Clinical trials recruiting for Prostate cancer
1,234
Recruiting trials
51
US states with sites
69
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Enzalutamide | 44 |
| Docetaxel | 29 |
| Darolutamide | 23 |
| Abiraterone acetate | 19 |
| Prednisone | 19 |
| Abiraterone | 18 |
| Apalutamide | 18 |
| Androgen Deprivation Therapy (ADT) | 16 |
| Carboplatin | 12 |
| Stereotactic Body Radiation Therapy | 11 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 10 |
| Pembrolizumab | 10 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 208 |
| New York | 174 |
| Texas | 160 |
| Florida | 134 |
| Massachusetts | 88 |
| Ohio | 88 |
| Maryland | 87 |
| Illinois | 86 |
| Pennsylvania | 86 |
| Michigan | 83 |
| Virginia | 79 |
| Washington | 78 |
Top cities
New York, New York 136Houston, Texas 107Los Angeles, California 89Boston, Massachusetts 81Seattle, Washington 68Nashville, Tennessee 62Chicago, Illinois 61San Francisco, California 60St Louis, Missouri 60Baltimore, Maryland 52
Self-screener
Recruiting trials
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
- 2 Ablative RadioTherapy Treatments for Prostate Cancer
- 24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
- 3D1015 Injection for Patients With mCRPC
- 4-aminopyridine Treatment for Nerve Injury
- 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
- 64Cu-GRIP B in Patients With Advanced Malignancies
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
- 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
- 68Ga-P3 PET/CT Imaging in Prostate
- 68Ga-PSMA PET/CT for Ra223 Assessment
- 68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk
- 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
- 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
- 68Ga-XACP3 PET/CT in Prostate Cancer
- 7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer
- 99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer
- 99mTc-P137 SPECT/CT in Prostate Cancer
- 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
- 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
- A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
- A Brief Psychological Intervention for Carer Fear of Cancer Progression
- A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
- A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
- A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
- A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer
- A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
- A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
- A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
- A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice
- A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
- A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
- A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
- A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- A Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors
- A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
- A Multi-center Investigation of Family Health.
- A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer
- A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
- A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
- A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
- A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
- A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
- A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
- A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer
- A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
- A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
- A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- A Phase 2/3,PSMA-T4, Prostate Cancer
- A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
- A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
- A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
- A Phase I Trial of A-CAR032 in Participants With mCRPC
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
- A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
- A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
- A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
- A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
- A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
- A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
- A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
- A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
- A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers
- A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
- A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery
- A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
- A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of Changes to Prostate Procedures
Related conditions
Trials recruiting for Prostate cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Lung cancer 2180Colorectal cancer 1359Metastatic Castration Resistant Prostate Cancer 67Pancreatic cancer 870Prostate Adenocarcinoma 52Metastatic Prostate Cancer 45Prostate Cancer (Adenocarcinoma) 43Ovarian cancer 118Prostatic Neoplasms 36
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Prostate cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.